ABBV vs MRK stock comparison
AbbVie vs. Merck & Co. · data as of November 13, 2026
AbbVie (ABBV) has a market value of about $521.5B, Merck & Co. (MRK) about $364.3B. Over their latest twelve months AbbVie had revenue of $66.0B and Merck & Co. $67.4B.
On our five checks Merck & Co. scores higher: 2.8 out of 5 (average) against 1.8 (weak).
By area, the stronger company is Merck & Co. on future growth; Merck & Co. on track record; Merck & Co. on shareholder returns.
AbbVie is cheaper on earnings (P/E 50.8 vs. 150.8), while Merck & Co. grew revenue faster over five years (9.4% vs. 5.9% a year).
AbbVie leads on 8 of the compared lines and Merck & Co. on 14.
Side by side
| ABBV | MRK | |
|---|---|---|
| Size and price | ||
| Market cap | $521.5B | $364.3B |
| Share price | $295.03 | $147.76 |
| Score | ||
| Overall score (of 5) | 1.8 | 2.8 |
| Value | 0 | 0 |
| Future growth | 1 | 2 |
| Track record | 2 | 5 |
| Financial health | 2 | 2 |
| Shareholder returns | 4 | 5 |
| Valuation | ||
| P/E (TTM) | 50.8 | 150.8 |
| Forward P/E | 19.1 | 17.6 |
| Price / free cash flow | 27.6 | 24.7 |
| Price / sales | 7.9 | 5.4 |
| EV / EBITDA | 19.8 | 32.5 |
| PEG | — | 7.10 |
| DCF value vs. price | −20% | −31% |
| Business | ||
| Revenue | $66.0B | $67.4B |
| Net income | $10.3B | $2.5B |
| Free cash flow | $18.9B | $14.7B |
| Net margin | 15.7% | 3.6% |
| Gross margin (5-yr avg.) | 68.3% | 73.4% |
| ROIC (5-yr avg.) | 15.3% | 16.3% |
| Growth | ||
| Revenue growth (1 yr) | 8.6% | 1.3% |
| Revenue growth (5 yrs, per year) | 5.9% | 9.4% |
| EPS growth (5 yrs, per year) | -2.8% | 21.2% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$61.5B | -$44.1B |
| Dividend yield | 2.35% | 2.30% |
| Shareholder yield | 2.5% | 3.7% |
| Analysts | ||
| Upside to average target | +6% | +9% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: ABBV TTM to September 30, 2026, MRK TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, AbbVie or Merck & Co.?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Merck & Co. scores 2.8 out of 5 and AbbVie 1.8; the table shows where each one is stronger.
Is AbbVie cheaper than Merck & Co.?
On trailing earnings, AbbVie trades at a P/E of 50.8 and Merck & Co. at 150.8, so AbbVie is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, AbbVie or Merck & Co.?
Over five years Merck & Co. grew revenue about 9.4% a year and AbbVie about 5.9% a year.
Which pays a higher dividend?
AbbVie yields 2.35% and Merck & Co. 2.30%.
Full AbbVie analysis → Full Merck & Co. analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.